Keystone Conference 2018

21st Century Drug Discovery and Development for Global Health

17-20 October 2018
Berlin, Germany

  • Nathalie Strub-Wourgaft, NTD Director – presentation on the new therapies for sleeping sickness
  • Charles Mowbray, Discovery Director – presentation on new orally active treatments for leishmaniasis

National Regulatory Conference (NRC) 2018

2-4 October 2018
Selangor, Malaysia

  • Marion Laumonier, Head of Regulatory Affairs – presentation on registration pathways and forum discussion on collaborative efforts between regulators and stakeholders

ISNTD 2018

25-26 June 2018 
London, UK
Ivan Scandale, Senior Project Manager, Discovery – presentation on the filarial research landscape
Eric StobbaertsInternational Development Director – presentation on access to Chagas treatments in Latin America

DNDi welcomes Astellas to the NTD Drug Discovery Booster

The Japanese pharmaceutical company Astellas Pharma Inc. is the eighth pharmaceutical company to join the Neglected Tropical Diseases Drug Discovery Booster, a global consortium launched in 2015 by DNDi to speed up the process and cut the cost of finding new treatments for leishmaniasis and Chagas disease.

DNDi, GlaxoSmithKline, and University of Dundee to identify drug candidates to treat leishmaniasis and Chagas disease

Geneva / Brentford / Dundee – 27 March 2018
The not-for-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) will collaborate with GlaxoSmithKline (GSK), and the University of Dundee Drug Discovery Unit (DDU), in a bid to discover new pre-clinical drug candidates targeting two parasitic neglected tropical diseases (NTDs), leishmaniasis and Chagas disease.